Birdwatch Note
2024-11-10 04:58:21 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
抗がん剤に極僅かながら何年か後に二次がんのリスクがあるのは事実です https://www.hosp.ncgm.go.jp/cancer/021/after_breastCancer/contents/new-cancer.html そのため、健康な人には百害あって一利なしなのでばく露防止対策を講じます https://www.mhlw.go.jp/content/11300000/000495981.pdf しかし、がん患者にはそれを上回る効果があるため世界中で使用されています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment https://answers.ten-navi.com/pharmanews/16470/ https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 日本のがんの年齢調整死亡率は減少しておりG7で最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm https://www.jstage.jst.go.jp/article/geriatrics1964/43/1/43_1_62/_pdf/-char/ja 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されます https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://www.ejim.ncgg.go.jp/pro/communication/c03/47.html https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1855426352423502322
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1855475059902812580
- noteId - 1855475059902812580
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1731214701997
- tweetId - 1855426352423502322
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 抗がん剤に極僅かながら何年か後に二次がんのリスクがあるのは事実です https://www.hosp.ncgm.go.jp/cancer/021/after_breastCancer/contents/new-cancer.html そのため、健康な人には百害あって一利なしなのでばく露防止対策を講じます https://www.mhlw.go.jp/content/11300000/000495981.pdf しかし、がん患者にはそれを上回る効果があるため世界中で使用されています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment https://answers.ten-navi.com/pharmanews/16470/ https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 日本のがんの年齢調整死亡率は減少しておりG7で最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm https://www.jstage.jst.go.jp/article/geriatrics1964/43/1/43_1_62/_pdf/-char/ja 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されます https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://www.ejim.ncgg.go.jp/pro/communication/c03/47.html https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Note Ratings
| rated at | rated by | |
| 2024-11-10 18:59:23 -0600 | Rating Details | |
| 2024-11-10 18:11:06 -0600 | Rating Details | |
| 2024-11-10 18:00:16 -0600 | Rating Details | |
| 2024-11-10 17:08:27 -0600 | Rating Details | |
| 2024-11-10 16:30:17 -0600 | Rating Details | |
| 2024-11-10 16:28:22 -0600 | Rating Details | |
| 2024-11-10 16:25:05 -0600 | Rating Details | |
| 2024-11-10 15:42:51 -0600 | Rating Details | |
| 2024-11-10 11:34:32 -0600 | Rating Details | |
| 2024-11-10 11:21:16 -0600 | Rating Details | |
| 2024-11-10 10:19:11 -0600 | Rating Details | |
| 2024-11-10 07:43:51 -0600 | Rating Details | |
| 2024-11-10 03:39:00 -0600 | Rating Details | |
| 2024-11-10 03:23:59 -0600 | Rating Details | |
| 2024-11-10 01:56:42 -0600 | Rating Details | |
| 2024-11-10 00:53:09 -0600 | Rating Details | |
| 2024-11-10 00:44:07 -0600 | Rating Details | |
| 2024-11-10 00:42:17 -0600 | Rating Details | |
| 2024-11-10 00:36:33 -0600 | Rating Details | |
| 2024-11-10 00:12:45 -0600 | Rating Details | |
| 2024-11-10 00:02:05 -0600 | Rating Details | |
| 2024-11-09 23:36:28 -0600 | Rating Details | |
| 2024-11-09 23:30:25 -0600 | Rating Details | |
| 2024-11-09 23:02:26 -0600 | Rating Details | |
| 2024-11-09 23:01:11 -0600 | Rating Details | |
| 2024-11-09 23:00:02 -0600 | Rating Details | |
| 2024-11-11 22:34:56 -0600 | Rating Details | |
| 2024-11-11 18:04:37 -0600 | Rating Details | |
| 2024-11-11 13:46:57 -0600 | Rating Details | |
| 2024-11-11 06:30:28 -0600 | Rating Details | |
| 2024-11-11 06:10:57 -0600 | Rating Details | |
| 2024-11-11 04:33:38 -0600 | Rating Details | |
| 2024-11-11 04:09:27 -0600 | Rating Details | |
| 2024-11-11 02:57:15 -0600 | Rating Details | |
| 2024-11-10 22:24:47 -0600 | Rating Details | |
| 2024-11-10 19:39:48 -0600 | Rating Details | |
| 2024-11-10 19:17:25 -0600 | Rating Details | |
| 2024-11-10 18:59:08 -0600 | Rating Details | |
| 2024-11-10 14:38:55 -0600 | Rating Details | |
| 2024-11-10 12:57:47 -0600 | Rating Details | |
| 2024-11-10 10:43:14 -0600 | Rating Details | |
| 2024-11-10 06:15:45 -0600 | Rating Details | |
| 2024-11-10 02:22:39 -0600 | Rating Details | |
| 2024-11-10 01:03:50 -0600 | Rating Details | |
| 2024-11-10 00:33:04 -0600 | Rating Details | |
| 2024-11-11 07:57:27 -0600 | Rating Details | |
| 2024-11-11 04:23:44 -0600 | Rating Details | |
| 2024-11-10 20:00:10 -0600 | Rating Details | |
| 2024-11-16 00:34:27 -0600 | Rating Details | |
| 2024-11-15 23:22:04 -0600 | Rating Details |